Latest filings (excl ownership)
15-12B
Securities registration termination
29 Nov 21
EFFECT
Notice of effectiveness
26 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
POS AM
Prospectus update (post-effective amendment)
19 Nov 21
8-K
Entry into a Material Definitive Agreement
19 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
19 Nov 21
SC TO-T/A
Third party tender offer statement (amended)
19 Nov 21
25-NSE
Exchange delisting
19 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
18 Nov 21
SC TO-T/A
Third party tender offer statement (amended)
18 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
17 Nov 21
10-Q
2021 Q3
Quarterly report
12 Nov 21
SC TO-T/A
Third party tender offer statement (amended)
12 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
12 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
1 Nov 21
SC TO-T/A
Third party tender offer statement (amended)
1 Nov 21
SC 14D9
Tender offer solicitation
22 Oct 21
SC TO-T
Third party tender offer statement
22 Oct 21
SC14D9C
Written communication relating to third party tender offer
12 Oct 21
SC TO-C
Information about tender offer
12 Oct 21
8-K
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
12 Oct 21
10-Q
2021 Q2
Quarterly report
4 Aug 21
8-K
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results
4 Aug 21
8-K
Departure of Directors or Certain Officers
12 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
25 Jun 21
10-Q
2021 Q1
Quarterly report
12 May 21
8-K
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
12 May 21
8-K
Regulation FD Disclosure
11 May 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
8-K
Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021
13 Apr 21
8-K
Departure of Directors or Certain Officers
5 Apr 21
Latest ownership filings
SC 13G
Newtyn Management, LLC
24 Nov 21
4
Change in insider ownership
23 Nov 21
3
Initial statement of insider ownership
23 Nov 21
4
Mark Stejbach
19 Nov 21
4
ALAN MILINAZZO
19 Nov 21
4
C ANN MERRIFIELD
19 Nov 21
4
Heath Lukatch
19 Nov 21
4
Elizabeth Kwo
19 Nov 21
4
Utpal Koppikar
19 Nov 21
4
SAMUEL D COLELLA
19 Nov 21
4
Scott A Canute
19 Nov 21
4
PATRICK J MAHAFFY
19 Nov 21
4
Mark S. Levine
19 Nov 21
4
Adam Muzikant
19 Nov 21
4
Kerry Wentworth
19 Nov 21
4
Melissa Layman
19 Nov 21
4
Christina Willwerth
19 Nov 21
4
FREDERICK W DRISCOLL
19 Nov 21
4
William T. Andrews
19 Nov 21
4
Michael D. Clayman
19 Nov 21
SC 13G/A
WASATCH ADVISORS INC
9 Nov 21
4
William T. Andrews
4 Aug 21
4
Christina Willwerth
20 Jul 21
4
Kerry Wentworth
20 Jul 21
4
Adam Muzikant
20 Jul 21
4
Mark S. Levine
20 Jul 21
4
Michael D. Clayman
20 Jul 21
4
Utpal Koppikar
12 Jul 21
3
Utpal Koppikar
12 Jul 21
3
William T. Andrews
6 Jul 21
4
Elizabeth Kwo
28 Jun 21
4
C ANN MERRIFIELD
28 Jun 21
4
Scott A Canute
28 Jun 21
4
SAMUEL D COLELLA
28 Jun 21
4
Mark Stejbach
28 Jun 21
4
Heath Lukatch
28 Jun 21
4
PATRICK J MAHAFFY
28 Jun 21
4
ALAN MILINAZZO
28 Jun 21
4
Adam Muzikant
28 Jun 21
4
Kerry Wentworth
28 Jun 21